Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate

British Journal of Clinical Pharmacology
L BorgströmJ Paulson

Abstract

1. The pharmacokinetics of the two enantiomers of terbutaline, (+)T and (-)T, and the racemate (+/-)T, have been evaluated after single intravenous and oral dosage to six healthy volunteers. 2. The mean systemic clearance, CL, was 0.19 and 0.13 l h-1 kg-1 for (+)T and (-)T, respectively. This difference was statistically significant. The mean clearance of (+/-)T was 0.20 l h-1 kg-1. Volumes of distribution were similar (1.9 l kg-1) after the three intravenous administrations. The differences in CL were reflected in values of the elimination half-life and MRT. 3. The difference in CL of the isomers could be explained by a corresponding difference in their renal clearance, CLR. Competition for stereoselective active reabsorption in the tubule might explain why (+)T seemed to enhance the CLR of (-)T when the drug was given as the racemate. 4. Oral bioavailability, calculated from plasma data, of (+)T was 7.5% and that of (-)T was 14.8%. This difference was statistically significant and was mainly due to a difference in absorption of (+)T and (-)T, but also to a difference in their subsequent first-pass metabolism. The bioavailability of (+/-)T was similar to that of (-)T. 5. (-)T appears to govern the absorption properties of the ...Continue Reading

References

Jun 1, 1986·Clinical Pharmacology and Therapeutics·D F WuM Z Wang
Nov 1, 1986·Clinical Pharmacology and Therapeutics·D A NottermanM M Reidenberg
May 1, 1985·British Journal of Clinical Pharmacology·E J LeeD Champion
Nov 1, 1985·The Journal of Clinical Investigation·P H Hsyu, K M Giacomini
Nov 1, 1972·Journal of Medicinal Chemistry·K Wetterlin
Jan 1, 1984·European Journal of Clinical Pharmacology·E J Ariëns
Jan 1, 1983·Annual Review of Pharmacology and Toxicology·C R Ross, P D Holohan
Apr 1, 1984·British Journal of Clinical Pharmacology·M EichelbaumB Vogelgesang
Jun 1, 1984·Clinical Pharmacology and Therapeutics·L S OlanoffT E Gaffney
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L BorgströmR Lenander
Nov 1, 1981·British Journal of Clinical Pharmacology·J GodbillonE Jähnchen
Jan 1, 1981·European Journal of Clinical Pharmacology·L BalantJ Fabre
Jun 1, 1980·Biomedical Mass Spectrometry·S E JacobssonL A Svensson

❮ Previous
Next ❯

Citations

Mar 21, 1998·Chirality·D A HandleyJ Morley
Jan 1, 1990·European Journal of Clinical Pharmacology·L BorgströmB Angelin
Jan 1, 1993·European Journal of Clinical Pharmacology·G M PacificiL Giuliani
Jan 1, 1996·Clinical Reviews in Allergy & Immunology·T WalleG R Pesola
Jan 1, 1996·Clinical Reviews in Allergy & Immunology·D W Boulton, J P Fawcett
Apr 1, 1990·European Journal of Drug Metabolism and Pharmacokinetics·D B Campbell
Aug 1, 2013·European Journal of Clinical Pharmacology·Anders BastiansenErland Pedersen
Jun 4, 2011·Journal of Molecular Modeling·Ranajit N ShindeM Elizabeth Sobhia
Apr 19, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Selma Sahin, Yasemin Karabey
Jan 1, 1990·Acta Pharmaceutica Nordica·G T Tucker
Jun 4, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Erik SjögrenChrister Tannergren
Jan 25, 2003·Journal of Biochemical and Biophysical Methods·Antonio Marzo, Erich Heftmann
Dec 1, 1994·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·E V Capparelli
Jul 27, 2001·Current Opinion in Chemical Biology·P R ChaturvediA Odinecs
Mar 13, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·M RoigJ Segura
Jun 12, 2003·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·D Bohn, N Kissoon
Jul 1, 1990·British Journal of Clinical Pharmacology·T Walle, U K Walle
Jan 1, 1996·British Journal of Clinical Pharmacology·D W Boulton, J P Fawcett
May 1, 1995·The Journal of Pharmacy and Pharmacology·K Takács-NovákG Szász
Oct 6, 1999·American Journal of Respiratory and Critical Care Medicine·R DhandM J Tobin
Mar 10, 2001·Clinical Pharmacokinetics·D W Boulton, J P Fawcett
Jan 24, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Nuggehally R Srinivas
Sep 2, 2003·Molecular Reproduction and Development·Béla Endre ReschGeorge Falkay
Jan 30, 2004·Journal of Clinical Pharmacology·Dietrich TürckTorsten Slowinski
Oct 4, 2007·The Journal of Pharmacy and Pharmacology·Urban Fagerholm
Jul 20, 2007·The Journal of Pharmacy and Pharmacology·Urban Fagerholm
Jan 1, 2004·Current Therapeutic Research, Clinical and Experimental·Daniel J LebovitzMichael D Reed
Feb 1, 1989·The Journal of Pediatrics·G FuglsangL Borgström
May 18, 1999·The Journal of Allergy and Clinical Immunology·B Waldeck
Oct 31, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H Lennernäs
Jul 1, 2011·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Md FaiyazuddinFarhan J Ahmad
Jul 5, 2016·Frontiers in Pharmacology·Anders DyreborgMorten Hostrup

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.